Inaprubahan ng FDA ang AbbVie SKYRIZI (risankizumab-rzaa) para sa pediatric psoriatic disease

FDA approved SKYRIZI for children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, including a new 55 mg pre-filled syringe for weight-based dosing in patients <40 kg. SKYRIZI is now the first and only IL-23 inhibitor approved in the U.S. for this pediatric population.

Mahahalagang fact

Na-file: Hun 26, 2026, 08:50 PM
Kaganapan: Pag-apruba ng FDA
Direksyon: Positibo
Kumpanya: ABBVAbbVie
Asset: risankizumab
Pinagmulan: Press release ng kumpanya
Kumpiyansa: May source

Sipi mula sa source

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease News provided by AbbVie Jun 26, 2026, 16:50 ET Share this article Share to X Share this article Share to X SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis NORTH CHICAGO, Ill. , June 26, 2026 /PRN

Press release ng kumpanya